Supriya Lifescience Limited (SUPRIYA)
Press Release for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed herewith.
Press Release - Q1FY27
- Revenue 189.75 Cr +31% y-y; EBITDA 47.46 Cr (margin 25.0%, -1060 bps y-y); PAT 24.04 Cr (margin 12.7%, -1130 bps y-y)
- Anesthetic segment largest at 48% revenue; Vitamins up to 17% from 11% in Q1FY26
- Asia largest market at 39% revenue; Europe 35%, LATAM 20%, North America 3%
- Export contribution strong at 81% of revenue
- New products: Cardiovascular and ADHD products scaling up; Liquid Anesthetic commercialized
- FY27 pipeline includes ~2 launches each in Anesthetic and ADHD segments
- Capacity utilization steady at 70%; total reactor capacity 932 KLPD
- Ambernath facility commissioned for finished dosage manufacturing
- R&D expanded with 68+ scientists and two new centers; plans 3-4 new products annually
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SUPRIYA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SUPRIYA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Supriya Lifescience Limited
Important.
The summary above is generated automatically from Supriya Lifescience Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.